WeLeader Biomedical Co., Ltd.

Total Valuation

WeLeader Biomedical Co., Ltd. carries a market capitalization of 3.22B, placing it among publicly traded companies globally. Its enterprise value stands at 3.81B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

WeLeader Biomedical Co., Ltd. currently has 45.48M shares outstanding.

Valuation Ratios

WeLeader Biomedical Co., Ltd. trades at a trailing price-to-earnings ratio of 15.73. The price-to-sales ratio is 2.96, and the price-to-book ratio stands at 4.20.

Enterprise Valuation

On an enterprise value basis, WeLeader Biomedical Co., Ltd. trades at an EV/EBITDA multiple of 14.59 and an EV/FCF ratio of 7.14. The EV/Sales ratio of 3.43 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 14.59 provides insight into valuation relative to core operating earnings.

Financial Position

WeLeader Biomedical Co., Ltd. maintains a current ratio of 1.81, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 68.54, indicating elevated leverage, while an interest coverage ratio of 32.57 demonstrates strong ability to service its debt obligations.

Financial Efficiency

WeLeader Biomedical Co., Ltd. posts a return on equity of 28.10 and a return on invested capital of 10.74.

Taxes

Over the trailing twelve months, WeLeader Biomedical Co., Ltd. has paid 52.43M in income taxes, reflecting an effective tax rate of 20.09.

Stock Price Statistics

WeLeader Biomedical Co., Ltd.'s stock has gained approximately 20.40816% over the past 52 weeks. The 50-day moving average sits at 68.32, while the 200-day moving average is 71.69.

Income Statement

Over the trailing twelve months, WeLeader Biomedical Co., Ltd. generated 1.11B in revenue and converted that into 208.56M in net income, yielding earnings per share of 4.65. EBITDA reached 261.13M, while operating income came in at 261.13M.

Balance Sheet

WeLeader Biomedical Co., Ltd. holds 334.71M in cash and equivalents against 863.64M in total debt, resulting in a net debt position of 262.27M. Total book value stands at 780.90M, with working capital of 348.08M providing operational flexibility.

Cash Flow

WeLeader Biomedical Co., Ltd. produced 313.30M in operating cash flow over the past twelve months. After subtracting -213.74M in capital expenditures, free cash flow totaled 99.55M - equivalent to 2.23 per share.

Margins

WeLeader Biomedical Co., Ltd. operates with a gross margin of 33.44, reflecting its pricing power and cost economics. The operating margin of 23.54 and net profit margin of 18.80 provide insight into operational efficiency.

Dividends & Yields

Scores

WeLeader Biomedical Co., Ltd. posts an Altman Z-Score of 2.82, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.